New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
DBS Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Cuts Target Price to $285
QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples
Stocks That Are Set to Benefit From Either Harris or Trump Winning Scenarios – Barclays
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Announces Target Price $265
BofA Securities analyst Travis Steed maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and sets the target price at $265.According to TipRanks data, the analyst has a success rate of 62.0%
Becton, Dickinson Launches Syringe With Thinner Wall Cannula